Evaluation of HER2 Mutations in Patient Tumors From E2598
18 Years
N/A
Both
Lung Cancer
Trial Information
Evaluation of HER2 Mutations in Patient Tumors From E2598
OBJECTIVES:
- Correlate clinical response to trastuzumab (Herceptin®) with the presence of mutation
in the HER-2 kinase domain in tumor samples from patients with advanced non-small cell
lung cancer treated on protocol ECOG-2598.
- Correlate mutations with time to progression and survival of these patients.
OUTLINE: This is a multicenter study.
Tissue specimens are analyzed by polymerase chain reaction to assess mutations in the HER-2
gene. Laboratory/biomarker analysis data is correlated with clinical data from protocol
ECOG-2598.
PROJECTED ACCRUAL: A total of 22-44 patients will be accrued for this study.
Inclusion Criteria
DISEASE CHARACTERISTICS:
- Diagnosis of non-small cell lung cancer meeting ≥ 1 of the following criteria:
- Recurrent disease
- Stage IIIB with pleural or pericardial effusion
- Stage IV disease
- Treated on protocol ECOG-2598
PATIENT CHARACTERISTICS:
- Not specified
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
Type of Study:
Observational
Study Design:
N/A
Outcome Measure:
Correlation of HER-2 mutation with response, time to progression, and survival
Safety Issue:
No
Principal Investigator
David P. Carbone, MD, PhD
Investigator Role:
Study Chair
Investigator Affiliation:
Vanderbilt-Ingram Cancer Center
Authority:
Unspecified
Study ID:
CDR0000476582
NCT ID:
NCT00896909
Start Date:
Completion Date:
Related Keywords:
- Lung Cancer
- recurrent non-small cell lung cancer
- stage IIIB non-small cell lung cancer
- stage IV non-small cell lung cancer
- Carcinoma, Non-Small-Cell Lung
- Lung Neoplasms
Name | Location |
|---|
